BioAtla Investor Presentation Deck

Phase 2 CAB-AXL (BA3011) Non-Squamous NSCLC Monotherapy 1.8 mg/kg Q2W shows encouraging efficacy signals Prior PD-1/L1 treatment EGFR wild-type (N=15) Data Cut Date: 30Jun23 Best Overall Response, n (%) Confirmed Partial Response Unconfirmed Partial Response Stable Disease Progressive Disease NA (early discontinuation due to AE) Response Rate n (%) Exact 95% CI Disease Control Rate n (%) Exact 95% CI bicatla 3 (20.0) 2 (13.3) 7 (46.7) 2 (13.3) 1 (6.7) 5 (33.3) 11.8, 61.6 8 (53.3) 26.6, 78.7 Monotherapy median Duration of Response was estimated to be 4.8 months with a range of 2.3-12.1+ months* Combination therapy (n=17)*: Prior PD-1/L1 treatment (N=18) Evaluable patients (majority with 4+ prior lines of therapy) received BA3011 + nivolumab One patient experienced an ongoing complete response (CR), 2 patients experienced PR, and 8 patients experienced stable disease (SD) Rotow J, Dy GK, Camidge DR. Poster presented at: International Association for the Study of Lung Cancer 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, IL. 3 (16.7) 2 (11.1) 10 (55.6) 2 (11.1) 1 (5.6) 5 (27.8) 9.7, 53.5 10 (55.6) 30.8, 78.5 *As of November 20, 2023 BioAtla| Overview 33

View entire presentation